Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine

(2010) G. Metro et al.   ANNALS OF ONCOLOGY

Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer

(2009) Rupert Bartsch et al.   BMC CANCER

Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients

(2009) Y H Park et al.   BRITISH JOURNAL OF CANCER

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

(2009) N. U. Lin et al.   CLINICAL CANCER RESEARCH

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

(2009) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Defining prognosis for women with breast cancer and CNS metastases by HER2 status

(2008) S. Dawood et al.   ANNALS OF ONCOLOGY

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

(2008) David Cameron et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2008) Nancy U. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Central Nervous System Metastases in HER-2-Overexpressing Metastatic Breast Cancer: A Treatment Challenge

(2008) H.-J. Stemmler et al.   ONCOLOGIST